Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Partnering on PTSD
February 2019
SHARING OPTIONS:

PORTLAND, Ore.—A collaboration is underway between Nobilis Therapeutics, a biopharmaceutical company advancing CNS therapies based on noble gas mixtures, and The Linde Group to support Nobilis’ clinical research program regarding a drug/device combination to treat post-traumatic stress disorder (PTSD). While specific terms were not released, the agreement states that Nobilis and Linde will collaborate to develop options regarding future supply, manufacturing and commercialization for such a product in the U.S., Europe, Latin America and Asia Pacific markets. The partners will create a joint steering committee to collaborate on the ongoing research and development plans.
 
“Our preclinical and early efficacy studies in PTSD, panic disorder, [and] autism spectrum disorder suggest the general potential for such drug/device combination to be a promising therapeutic option for the treatment of patients with post-traumatic stress disorder, and potentially other psychiatric and neurodegenerative conditions,” said Dr. Vlad Bogin, founder and CEO of Nobilis Therapeutics.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.